MedTrace Logo

Clinical Utilization of Newly Approved Oncology Medications

NCT02783885 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-05-26

No results posted yet for this study

Summary

The efficacy and safety of different medications vary from one individual to another and from one ethnic group to another. Therefore, strong interest in the study of pharmacogenomic and pharmacoepidemiology has evolved recently.

There are multiple examples of oncology drugs being more effective in certain ethnic population compared to other. For example, irinotecan combined with cisplatin was very effective drug in the management of small cell lung cancer in the Japanese patients while an identical study done in the US revealed no major benefit to this combination in American population

Conditions

Interventions

DRUG

immunotherapy

Sponsors & Collaborators

  • National Guard Health Affairs

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02783885 on ClinicalTrials.gov